The Department of Hematology, Transplantation and Internal Medicine at UCC MUW has been accredited to use genetically modified CAR-T lymphocytes by Novartis - Kymriah product.
The department became the third center in Poland treating adults with permission to use this technology. CAR T cells will be used to treat patients with refractory/relapsed diffuse large B-cell lymphoma (DLBCL) and B-cell acute lymphoblastic leukemia (B-ALL) up to age 26. Work is also underway to use CAR-T lymphocytes from other manufacturers in hospital exemption and clinical trials. Thus, the center joins the leading European centers using this innovative technology.